Search the Newsreel

Lifecore Signs Six New Programs, Including Two Commercial-Stage

Lifecore Biomedical reported Q2 2026 revenues of $34.2 million, a 6.2% decrease year-over-year, and a net loss of $6.2 million. Despite the revenue decline, the company reaffirmed its 2026 guidance for revenues of $120–$125 million and Adjusted EBITDA of $20.5–$25 million, citing strong business …

Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed

Lifecore Biomedical reported a decline in Q2 2026 revenue to $34.2 million and an increased net loss of $6.2 million, despite growth in hyaluronic-acid manufacturing. The company reaffirmed its full-year 2026 guidance for revenue ($120-$125 million) and Adjusted EBITDA ($20.5-$25 million), highlighting a strong …

Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026

Lifecore Biomedical, Inc. has reaffirmed its earnings guidance for the calendar year 2026, expecting revenue to be in the range of $120 million to $125 million. This announcement was made on August 5, 2026, coinciding with their Q2 2026 earnings call. The company specializes …

Darren Sherman Sells 15,000 Shares of Orchestra BioMed (NASDAQ:OBIO) Stock

Orchestra BioMed (OBIO) insider sale under 10b5-1 plan on August 3, 2026

Orchestra BioMed Holdings, Inc. executive Darren Sherman sold 15,000 shares of common stock on August 3, 2026, at a weighted average price of $4.09 per share under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Sherman directly holds 1,154,327 shares. The sale ranged …

Orchestra BioMed (OBIO) Projected to Announce Quarterly Earnings on Tuesday

Orchestra BioMed (OBIO) is projected to announce its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $0.35 per share and revenue of $138,000. The company previously beat EPS expectations but missed revenue targets in Q1. The …

CervoMed Inc expected to post a loss of 87 cents a share - Earnings Preview

CervoMed Inc is expected to report an upcoming earnings loss of 87 cents per share. This information, provided by Refinitiv and featured on TradingView News, is part of an earnings preview.

Price to earnings forward of Ondine Biomedical, Inc. – LSE:OBI

CervoMed (NASDAQ: CRVO) receives UK ILAP Innovation Passport for DLB drug

CervoMed Inc. announced that its lead drug candidate, neflamapimod, has been granted an Innovation Passport by the UK, allowing its entry into the Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). This designation is designed to accelerate …

CervoMed Announces Neflamapimod Awarded Innovation Passport

CervoMed announced that its drug candidate, neflamapimod, has received an Innovation Passport under the UK's Innovative Licensing and Access Pathway (ILAP) for treating Dementia with Lewy Bodies (DLB). This designation aims to accelerate market access and facilitate patient access to new medicines in the …

GDTC|CytoMed Therapeutics Ltd|Price:0.960|Chg%:+0.030

This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its current stock price, market cap, key financial figures, and recent performance. It highlights the company's focus on developing cell-based immunotherapies for cancer, specifically utilizing gamma delta T cell and natural …

Orchestra BioMed (NASDAQ: OBIO) insider details Rule 144 sales of 45,000 shares

An insider at Orchestra BioMed Holdings Inc. (OBIO) has filed to sell 15,000 shares of common stock under Rule 144, valued at $61,291.68, scheduled for August 3, 2026. The shareholder, Darren Sherman, also reported previous sales of 15,000 shares each on June 1, 2026, …

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

Faruqi & Faruqi, LLP is investigating potential securities claims against Lifecore Biomedical, Inc. (NASDAQ: LFCR) on behalf of investors who suffered losses exceeding $75,000 between October 7, 2020, and March 19, 2024. The investigation stems from allegations that Lifecore made false or misleading statements …

Laba Bersih Jayamas Medica Tumbuh 43,2 Persen pada Semester I 2026

Orchestra Biomed Holdings Inc (OBIO) Institutional Confidence

Orchestra Biomed Holdings Inc (OBIO) has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 7.86% quarter-over-quarter to 42.19%, with Steven Cohen being the largest institutional shareholder.

Orchestra Biomed Holdings Inc (OBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Orchestra Biomed Holdings Inc (OBIO), detailing its current price momentum score, support and resistance levels, and the status of various technical indicators and moving averages. The analysis suggests the stock is currently trading between identified support and …

Lifecore Biomedical Inc (LFCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lifecore Biomedical Inc (LFCR), focusing on its price momentum, support and resistance levels, and various technical indicators, including moving averages. The current price momentum score is 4.32, with the stock trading between a resistance level of 5.16 …

CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown for CytoMed Therapeutics Ltd (GDTC), noting that relevant data regarding business segments and regional revenue contributions have not been disclosed by the company. It highlights the current stock price and market capitalization of GDTC. The primary message is …

Price to book forward of Orchestra BioMed Holdings, Inc. – NASDAQ:OBIO

This page provides financial data for Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO), specifically focusing on its price-to-book forward ratio. The content is primarily a data display with minimal narrative, indicating the company's financial overview on the TradingView platform.

CervoMed Inc (CRVO) Valuation: PE, PB & Fair Value Analysis

CervoMed Inc (CRVO) currently holds a valuation score of 6.43, placing it 301st out of 385 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is reported as -0.79, significantly below its recent high and above its recent low. Key valuation …

OMED posts IDR 219 billion first-half profit, up 42.74%

Biotech Stocks Surge with Advanced Biomed Leading Gains

Advanced Biomed (ADVB) experienced a significant stock price surge of over 211% this week, driven by strong investor interest in its microfluidic technology despite not yet having commercial sales. Other biotech companies like Novocure (NVCR), Medpace (MEDP), and SciSparc (SPRC) also showed substantial gains …

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Lifecore Biomedical, Inc. announced that it will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens. The company's senior management team will host a webcast at 8:00 a.m. Eastern Time on the …

Lifecore Sets Aug. 5 Webcast for Second-Quarter Results

Lifecore Biomedical (NASDAQ: LFCR) announced it will report its second-quarter financial results for the period ended June 30, 2026, on Wednesday, August 5, 2026, before market open. Senior management will host a webcast at 8:00 a.m. Eastern Time to discuss the results, with an …

Alpha Trust Andromeda Investment Trust SA Revenue Breakdown – ATHEX:ANDRO

BlackRock (LFCR holder) reports 2,010,546 Lifecore Biomedical shares in new ownership filing

BlackRock, Inc. has filed a Schedule 13G indicating a passive ownership stake in Lifecore Biomedical, Inc. (LFCR). BlackRock and its business units beneficially own 2,010,546 shares, representing 5.4% of Lifecore's common stock, with sole voting power over 1,988,535 shares and sole dispositive power over …

Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Lifecore Biomedical Inc (LFCR), a company within the Pharmaceuticals industry. It highlights that LFCR has a risk assessment score of 4.90, ranking 78 out of 155 in its industry, and a beta value of 1.07. The report …

How Oxford Biomedica (LSE:OXB) And GSK (LSE:GSK) Fit The Latest London Healthcare Stocks Story

CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of CytoMed Therapeutics Ltd (GDTC), detailing its current support, resistance levels, and the readings from various technical indicators and moving averages. According to the analysis, the overall signal is Neutral based on moving averages and other technical indicators, …

Lifecore Biomedical Inc (LFCR) Financial Health: Profitability & Balance Sheet Analysis

Lifecore Biomedical Inc (LFCR) currently holds a weak financial score of 6.79 out of 10, ranking 134th in the Pharmaceuticals industry. While its operating efficiency is high, the company reported a year-over-year revenue decrease of 6.12% and a net profit decrease of 1.82% in …

CRVO|CervoMed Inc|Price:2.555|Chg%:-0.005

This article provides a comprehensive stock analysis of CervoMed Inc (CRVO) by TradingKey. It highlights that CervoMed's fundamentals are healthy with significant growth potential, although its valuation is considered fairly valued within the Biotechnology & Medical Research industry. Analysts overwhelmingly rate it as a …

Lifecore Biomedical signs three new customer deals, boosting 2028 revenue outlook.

Lifecore Biomedical has secured three new customer agreements for early- and late-stage development programs, including a regenerative medicine project and a medical device formulation. These deals are expected to significantly contribute to the company's revenue growth by 2028. The agreements underscore Lifecore's broad technical …

Regenerative Medicine and Device Programs Expand Lifecore’s Pipeline

Lifecore Biomedical (NASDAQ: LFCR) has announced three new customer agreements that will expand its pipeline in regenerative medicine and advanced medical technologies. These agreements include a late-stage regenerative medicine program and two early-stage programs focusing on formulation optimization, which are expected to contribute to …

CervoMed Inc (CRVO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of CervoMed Inc (CRVO), outlining major individual and institutional holdings. Key individuals like Joshua S. Boger, Sylvie L. Gregoire, and John J. Alam hold significant proportions, alongside institutional investors such as Morgan Stanley. The report also includes quarterly …

Orchestra BioMed Hldgs Market Sentiment

This article provides an overview of market sentiment for Orchestra BioMed Holdings Inc (OBIO), detailing analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from seven analysts with an average price target of $14, and lists recent analyst actions …

Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Lifecore Biomedical Inc (LFCR), listing its major individual shareholders and the proportion of shares they hold. It also breaks down shareholder types, such as hedge funds and investment advisors, and provides institutional shareholding data over several quarters, …